A side-by-side comparison of two Healthcare investors: HSG (Power Score 85/100) and Vivo Capital (Power Score 83/100), both ranked among the most active firms tracked in this category.
| HSG | Vivo Capital | |
|---|---|---|
| Power Score™ | 85/100 | 83/100 |
| Assets Managed | Over US$61B (assets for institutional investors as of 30 June 2026, per hsgcap.com/about-us) | $6.1B ("Active AUM" as of Q4 2025, the label the firm uses on its own homepage; it separately stated approximately $5.3B of regulatory assets under management in its 7 May 2025 fund-close announcement) |
| Founded | 2005 | 1996 |
| Headquarters | Hong Kong, China | Palo Alto, CA |
| Sectors | Technology, Healthcare, Consumer | Healthcare, Biotech, Pharmaceuticals, Life Sciences, Healthtech |
HSG describes itself on its own About Us page as a venture capital and private equity firm, formerly known as Sequoia China, investing globally across technology, healthcare and consumer sectors. Its Chinese-language site describes the same three areas as 科技, 医疗 and 消费, and lists its investment stages as seed-stage, growth-stage, buyout, new-infrastructure and public-market investing (种子期投资, 成长期投资, 并购投资, 新基建投资, 公开市场投资). The firm states it has backed more than 1,800 companies, that over 190 of them have gone public and that over 140 have become unicorns. It states offices in Hong Kong, Shanghai, Beijing, Shenzhen, London, Tokyo and Singapore.
View full HSG profile →Vivo Capital describes itself as a global healthcare specialist running a multi-strategy investment platform that covers venture capital, private equity and public equity. Its investment strategy page names three distinct strategies: the Vivo Innovation Fund, which invests in venture-stage companies developing healthcare technologies or products; Vivo Capital Private Equity, which combines growth capital for companies at commercial inflection points with a buyout strategy covering leveraged buyouts, management buyouts, spin-offs and restructurings; and the Vivo Opportunity Fund, a long-only strategy investing primarily in global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies through follow-ons, PIPEs, registered directs and IPOs. The firm states it has invested in over 460 healthcare companies and operates from Palo Alto with offices in China and a presence in Singapore.
View full Vivo Capital profile →